As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...

Medical advances make pills to treat Alzheimer’s disease viable, though challenges remain in sharing gains globally ...

With an estimated 6.9 million Americans aged 65 and older currently living with Alzheimer’s disease, the road to a cure seems ...

D imaging and organoid models are revolutionizing dementia research, offering deeper insights into disease mechanisms and ...

A simple digital health tool developed by Australian researchers could soon help predict the age of onset for early Alzheimer ...

Nov. 19, 2024 — Common cardiovascular drugs are linked to a lower risk of dementia in older age, according to a new ... Earlier Diabetes Diagnosis Linked to Dementia Risk Nov. 19, 2024 ...

2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab) ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

Unhappily, oxybutynin hydrochloride, tolterodine tartrate and solifenacin succinate – the three linked to dementia – are considered the most effective drugs for treating overactive bladder.

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive ...

Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits ...

The first pill to slow down the progression of Alzheimer’s disease is being studied for use on the NHS ...